Benzinga · Aug 26, 2026
Why JOYY Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares rise 3.6% in pre-market trading.
NN
NASDAQ · NNNN
Anbio Biotechnology Class A Ordinary Shares
Healthcare · Medical - Instruments & Supplies
$6.34
Down-$0.17 (-2.61%)
Updated Sep 14, 2026, 10:13 AM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.28B
- P/E ratio
- 480.56
- Dividend yield
- 0.00%
- 52-week range
- $6.13 – $36.11
- Volume
- 268.77K
- Avg. volume
- 48.26K
Price performance
NNNN price history
1M range · 19 trading sessions · Daily adjusted prices
NNNN closed at $6.34 after 19 trading sessions, down 25.28% for the selected period.
- Last close
- $6.34
- Period change
- -25.28%
- Period low
- $6.34
- Period high
- $8.49
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $6.49 | $6.49 | $6.21 | $6.34 | 268.77K |
| Sep 10, 2026 | $6.32 | $6.51 | $6.1315 | $6.51 | 242.83K |
| Sep 9, 2026 | $6.37 | $6.51 | $6.13 | $6.47 | 259.53K |
| Sep 8, 2026 | $6.50 | $6.79 | $6.20 | $6.48 | 254.36K |
| Sep 4, 2026 | $6.58 | $6.77 | $6.36 | $6.54 | 231.15K |
| Sep 3, 2026 | $6.84 | $6.93 | $6.28 | $6.60 | 226.58K |
| Sep 2, 2026 | $7.14 | $7.1577 | $6.615 | $6.85 | 228.32K |
| Sep 1, 2026 | $7.32 | $7.3999 | $6.76 | $7.22 | 273.87K |
| Aug 31, 2026 | $7.50 | $7.76 | $7.0821 | $7.30 | 279.21K |
| Aug 28, 2026 | $7.72 | $7.915 | $7.35 | $7.67 | 252.35K |
| Aug 27, 2026 | $7.70 | $8.00 | $7.48 | $7.78 | 277.03K |
| Aug 26, 2026 | $7.85 | $8.27 | $7.41 | $7.72 | 278.21K |
| Aug 25, 2026 | $7.91 | $8.40 | $7.5505 | $7.83 | 234.16K |
| Aug 24, 2026 | $6.77 | $8.98 | $6.6409 | $7.90 | 268.86K |
| Aug 21, 2026 | $7.20 | $7.35 | $6.61 | $6.81 | 79.25K |
| Aug 20, 2026 | $7.82 | $7.82 | $7.22 | $7.33 | 44.35K |
| Aug 19, 2026 | $7.92 | $8.40 | $7.65 | $7.75 | 86.37K |
| Aug 18, 2026 | $8.50 | $8.6625 | $7.93 | $8.35 | 92.82K |
| Aug 17, 2026 | $10.17 | $13.7995 | $7.0801 | $8.485 | 1.29M |
Latest NNNN news
The latest Smart Investors Daily articles mentioning NNNN.
Stock researchCompany · Overview
NNNN research
Overview
Company profile and research snapshot.
Company profile
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Jun 18, 2026
Top 3 Health Care Stocks You'll Regret Missing In Q2
Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.
Yahoo · Apr 20, 2026
US Market's Hidden Gems: 3 Promising Small Caps
Over the last 7 days, the United States market has risen by 4.0%, and over the past year, it has seen a robust increase of 39%, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying promising small-cap stocks can offer unique opportunities for investors seeking growth potential beyond the well-trodden paths of larger companies.
Yahoo · Apr 16, 2026
Discovering 3 US Small Cap Gems with Promising Potential
The United States market has shown robust performance recently, climbing 3.4% in the last week and surging 35% over the past year, with earnings projected to grow by 16% annually in the coming years. In such a dynamic environment, identifying small-cap stocks with strong fundamentals and growth potential can be key to uncovering promising investment opportunities.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
